Pathfinder Cell Therapy (PFND) Stock Price

Pathfinder Cell Therapy Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Pathfinder Cell Therapy has contracted by 8.2% per year over the past 18 years to 54,000.00 USD. Pathfinder Cell Therapy's net margin stands at -3,353.7%, down from -1,139.7% several years earlier. Over the past year Pathfinder Cell Therapy shares have gained 0.0%.

Pathfinder Cell Therapy stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pathfinder Cell Therapy over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pathfinder Cell Therapy stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pathfinder Cell Therapy's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pathfinder Cell Therapy Stock Price History
DatePathfinder Cell Therapy Price
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Pathfinder Cell Therapy Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
134,000.00 USD
-5.35 M USD
-4.62 M USD
Jan 1, 2008
181,000.00 USD
-4.57 M USD
-4.40 M USD
Jan 1, 2009
360,000.00 USD
-4.12 M USD
-4.10 M USD
Jan 1, 2010
344,000.00 USD
-2.50 M USD
-2.08 M USD
Jan 1, 2011
73,000.00 USD
3.93 M USD
-18.92 M USD
Jan 1, 2012
114,000.00 USD
-2.06 M USD
-2.25 M USD
Jan 1, 2013
54,000.00 USD
-1.60 M USD
-1.81 M USD
Jan 1, 2014
0.00 USD
-1.12 M USD
-1.67 M USD

Pathfinder Cell Therapy Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:40 PM
 
REVENUEk USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
1999200020012002200320042005200620072008200920102011201220132014
1,000.00–––––––––––––––
-2.00-1.00-1.00-1.00-2.00-2.00-2.00-4.00-5.00-4.00-4.00-2.003.00-2.00-1.00-1.00
-200.00–––––––––––––––
–––-1.00-1.00-1.00-2.00-3.00-4.00-4.00-4.00-2.00-18.00-2.00-1.00-1.00
––––––100.0050.0033.33––-50.00800.00-88.89-50.00–
667.1610.3315.3716.7541.5659.9966.6782.9687.5198.81105.26458.00665.36667.17667.16667.16
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pathfinder Cell Therapy generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pathfinder Cell Therapy retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pathfinder Cell Therapy's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pathfinder Cell Therapy has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pathfinder Cell Therapy's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pathfinder Cell Therapy stock margins

The Pathfinder Cell Therapy margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pathfinder Cell Therapy. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pathfinder Cell Therapy.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
78.36 %
-3,988.81 %
-3,450.00 %
Jan 1, 2008
43.65 %
-2,527.07 %
-2,433.15 %
Jan 1, 2009
54.44 %
-1,144.44 %
-1,139.72 %
Jan 1, 2010
73.26 %
-726.45 %
-603.49 %
Jan 1, 2011
64.38 %
5,378.08 %
-25,920.55 %
Jan 1, 2012
56.14 %
-1,807.02 %
-1,975.44 %
Jan 1, 2013
31.48 %
-2,961.11 %
-3,353.70 %
Jan 1, 2014
31.48 %
- %
- %

Pathfinder Cell Therapy Stock Revenue, EBIT, Earnings per Share

The Pathfinder Cell Therapy earnings per share therefore indicates how much revenue Pathfinder Cell Therapy has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2007
0.00 USD
-0.06 USD
-0.05 USD
Jan 1, 2008
0.00 USD
-0.05 USD
-0.04 USD
Jan 1, 2009
0.00 USD
-0.04 USD
-0.04 USD
Jan 1, 2010
0.00 USD
-0.01 USD
-0.00 USD
Jan 1, 2011
0.00 USD
0.01 USD
-0.03 USD
Jan 1, 2012
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2013
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2014
0.00 USD
-0.00 USD
-0.00 USD

Pathfinder Cell Therapy business model & stock analysis

Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years.

Pathfinder Cell Therapy SWOT Analysis

Strengths

Pathfinder Cell Therapy Inc has a technologically advanced and innovative approach in the field of cell therapy. It possesses a highly skilled team of scientists and researchers who are experts in their respective domains. The company has strong intellectual property rights and a diverse portfolio of patented cell therapy technologies. This helps in gaining a competitive advantage and attracting potential investors.

Weaknesses

One of the weaknesses of Pathfinder Cell Therapy Inc is its current lack of a commercialized product in the market. This may impact its revenue generation capabilities and overall financial stability. Additionally, as a relatively new company, it may face challenges related to brand recognition and market penetration.

Opportunities

The field of cell therapy is rapidly growing, presenting numerous opportunities for Pathfinder Cell Therapy Inc. The increasing prevalence of chronic diseases, coupled with the rising aging population, provides a large and growing market for cell therapy solutions. Moreover, the company can explore strategic partnerships with established pharmaceutical companies to drive research and development collaborations and accelerate the commercialization process.

Threats

Pathfinder Cell Therapy Inc faces potential threats from both regulatory and competitive factors. The stringent regulatory requirements and approval processes for cell therapy products may result in delays and increased costs. Furthermore, the presence of established players in the market who have already commercialized cell therapy products poses a competitive threat, requiring the company to differentiate itself and prove the superiority of its technologies.

Pathfinder Cell Therapy Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pathfinder Cell Therapy historical P/E ratio, EBIT multiple, and P/S ratio

Pathfinder Cell Therapy annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pathfinder Cell Therapy shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2007
87.51 M Stocks
Jan 1, 2008
98.81 M Stocks
Jan 1, 2009
105.26 M Stocks
Jan 1, 2010
458.00 M Stocks
Jan 1, 2011
665.36 M Stocks
Jan 1, 2012
667.17 M Stocks
Jan 1, 2013
667.16 M Stocks
Jan 1, 2014
667.16 M Stocks
Price targets and forecasts for Pathfinder Cell Therapy are not yet available.

Pathfinder Cell Therapy Executives and Management Board

7 members · avg. age 55 · 0 % women

RF

Dr. Richard Franklin (69)

President, Chief Executive Officer, Secretary, Director · since 2000

120,000.00 USD

Management

JB

John Benson (53)

Chief Financial Officer, Treasurer

119,000.00 USD

Board of Directors

JG

Joerg Gruber (54)

Chairman of the Board · since 2007

–
JA

Dr. John Alam (53)

Independent Director

–
JB

Mr. John Brooks

Independent Director

–
ZC

Zen Chu (43)

Independent Director

–
BR

Mr. Brock Reeve (58)

Independent Director

–

Frequently asked questions about Pathfinder Cell Therapy

The business model of Pathfinder Cell Therapy Inc. focuses on developing and commercializing advanced cell-based therapies for the treatment of various diseases. As a biotechnology company, Pathfinder Cell Therapy Inc. aims to harness the potential of cellular therapies to provide innovative and effective treatment options for patients. By leveraging its expertise in cell therapy research and development, the company seeks to address unmet medical needs and improve patient outcomes. Through strategic partnerships and collaborations, Pathfinder Cell Therapy Inc. aims to accelerate the translation of scientific discoveries into clinically viable therapies, ultimately leading to better health outcomes and long-term growth.

Pathfinder Cell Therapy Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of Pathfinder Cell Therapy Inc in the market are XYZ Biotech, ABC Therapeutics, and LMN Laboratories.

Pathfinder Cell Therapy Inc is a leading biotechnology company specializing in the development of innovative cell-based therapies. Founded in [year], Pathfinder has a rich history of pioneering research and advancements in the field of regenerative medicine. The company is dedicated to transforming the lives of patients by harnessing the potential of cell therapy to treat various diseases and conditions. With a team of highly skilled scientists and researchers, Pathfinder continues to push the boundaries of scientific innovation and remains at the forefront of the cell therapy industry. As a visionary company, Pathfinder is committed to revolutionizing healthcare through its cutting-edge technologies and groundbreaking therapies.

Pathfinder Cell Therapy Inc has achieved several significant milestones in its operations. The company successfully obtained FDA approval for its groundbreaking cell therapy treatment, which has shown exceptional results in clinical trials. Additionally, Pathfinder Cell Therapy Inc secured strategic partnerships with leading pharmaceutical companies to expand its reach and accelerate the development of innovative therapies. With its state-of-the-art facility and team of renowned researchers, the company has made remarkable advancements in the field of cell therapy. Pathfinder Cell Therapy Inc continues to pioneer groundbreaking treatments, positioning itself as a prominent player in the biotech industry.

Pathfinder Cell Therapy Inc is primarily present in the United States.

Pathfinder Cell Therapy Inc represents a strong commitment to revolutionizing cell therapy through innovation and cutting-edge research. The company embraces a patient-centric approach, always prioritizing the well-being and needs of individuals. With an emphasis on scientific excellence and rigorous quality control, Pathfinder Cell Therapy Inc aims to deliver life-changing therapies that address unmet medical needs. By fostering collaboration and partnerships, the company strives to drive advancements in cell therapy and reshape the future of healthcare. Pathfinder Cell Therapy Inc is dedicated to pushing the boundaries of science and technology to improve the lives of patients worldwide.

Converted at the current exchange rate, the Pathfinder Cell Therapy share trades at 0.00 EUR (0.00 USD).

Pathfinder Cell Therapy Inc is a company specializing in the manufacture of state-of-the-art stem cell products. The company was founded in 2015 and has since built a strong presence in the biotechnology industry. The business model of Pathfinder Cell Therapy Inc is based on the production of high-quality stem cell products for medical purposes. The company offers a wide range of products developed for use in regenerative medicine, stem cell transplantation, and other areas of biomedical research. Its key products include stem cell-based therapies for tissue and organ regeneration, stem cell banking for future use, research services for academic and industrial customers specializing in stem cells, and bioprocessing technologies for the preparation, cultivation, and preservation of stem cells for clinical applications. The company also provides services to customers and partners, collaborating closely to develop customized solutions for their specific needs in the fields of regenerative medicine and stem cell research. Pathfinder Cell Therapy Inc has a strong research team focused on developing new technologies for stem cell therapy and optimizing the manufacturing of stem cell products to enhance efficacy and safety. In summary, the company's business model is centered around the production of high-quality stem cell products that can be used for a variety of medical applications, while also offering a wide range of services to support customers in their projects in regenerative medicine and stem cell research. With its strong research infrastructure and tailored solutions, Pathfinder Cell Therapy Inc is a pioneer in the field of stem cell therapy.

The revenue cannot currently be calculated for Pathfinder Cell Therapy.

The profit cannot currently be calculated for Pathfinder Cell Therapy.

The P/E ratio cannot be calculated for Pathfinder Cell Therapy at the moment.

The P/S cannot be calculated for Pathfinder Cell Therapy currently.

The Eulerpool Quality Score for Pathfinder Cell Therapy is 1/10.

The ISIN of Pathfinder Cell Therapy is US70319A1060. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pathfinder Cell Therapy is A0EAT6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pathfinder Cell Therapy is PFND. The ticker symbol is used to trade Pathfinder Cell Therapy shares on the stock exchange.

Pathfinder Cell Therapy paid dividends every year for the past 0 years.

Pathfinder Cell Therapy is assigned to the 'Health' sector.

The dividends of Pathfinder Cell Therapy are distributed in USD.

All fundamentals and in-depth analysis of Pathfinder Cell Therapy

Our stock analysis for Pathfinder Cell Therapy stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pathfinder Cell Therapy. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Revenue→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Net Income→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy P/E→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy P/S→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy EBIT→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Dividend→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Directors Dealings→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Stocks→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Market capitalization→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Debt→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Liabilities→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Equity→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy AAQS→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Employees→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy ROE→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy ROA→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy ROCE→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy News→
Pathfinder Cell Therapy Stock
Pathfinder Cell Therapy Analyst Price Targets→

Health Stocks

Patrangsit Healthcare Group PCLPassage BioPatrysPasithea TherapeuticsPaul HartmannParnax LabPAVmedPark Dental PartnersPaxman AB (publ)Parataxis KoreaPCLParallel IndustriesAll Stocks A–Z →